MondayAug 07, 2017 1:56 pm

Moleculin Biotech (NASDAQ: MBRX) to Begin Preparing Clinical Testing Sites for Leukemia Treatment

NASDAQ Biotechnology Index up and climbing Developing new treatment for acute myeloid leukemia (AML) Lead candidate, Annamycin, now at phase II Since a rising sea lifts all boats, it’s decidedly good news for Moleculin Biotech, Inc. (NASDAQ: MBRX) that the NASDAQ Biotechnology Index (NBI) is enjoying a spring tide. The index has offered a year-to-date return of over 17 percent and seems set to keep climbing. This benign environment gives Moleculin an opportunity to advance work on its leading anti-cancer drug candidates. The company has begun to identify and prepare testing sites in Europe and has already appointed a Lead…

Continue Reading

MondayAug 07, 2017 12:42 pm

Medical Innovation Holdings, Inc. (MIHI) Serving the Underserved with Telemedicine

Millions of Americans live in areas with little or no comprehensive health care MIHI establishing nationwide telemedicine network to provide specialty care Serving the underserved makes MIHI sole practitioner to millions There’s no doubt that the U.S. health care system is fractured. Our patchwork quilt of health care services leaves many citizens isolated and medically stranded. Far beyond the current contentious health care debate, millions of Americans live in areas that have chronically suffered with little or no health care services. For various reasons of geography, economics or social circumstance, certain populations in the country have far too few primary…

Continue Reading

FridayAug 04, 2017 3:24 pm

7 Company Updates from this Week to Review

The last week has been quite busy for the global marijuana industry as companies continued to execute and work to create value for shareholders. Although the marijuana industry is comprised of some incredible companies, investors must be selective and focus on the real players. Today we have highlighted 7 developments that marijuana stock investors need to know about. Insys: Second Quarter Revenue Drops 38% Nasdaq-traded Insys Therapeutics (INSY) reported its second quarter financial results today and recorded a 38% drop in revenue when compared to the same quarter last year. Although this biotech cannabis stock has continued to execute, the…

Continue Reading

WednesdayAug 02, 2017 12:32 pm

Algae Dynamics Corp. (ADYNF) Targets Smokeless Medical Cannabis Market, Partners with Major Universities for Research

Good investment opportunities exist in the marijuana boom, but caution is urged Choosing companies with access to the legal medical marijuana space can help investors avoid the risk of changing regulations Algae Dynamics Corp. is focusing on cannabis oil extraction and medicine delivery systems to provide the medical benefits without having to smoke ADYNF is partnering with two major universities to research the use of cannabis oil extracts for cancers and novel mental health treatments Everyone knows there is money to be made in marijuana these days. Americans already spend more on cannabis than ice cream each year, and Canadians…

Continue Reading

ThursdayJul 27, 2017 9:00 am

Biotech Players Lead the Growth Charge in the Legal Cannabis Market

CBDWire Editorial Coverage: The backbone of medical advancement is biotechnology, an industry wrought with the incredible potential of novel drug R&D, but vulnerable to the risk of stringent regulatory approval processes. Within this volatile market, however, is the cannabis-biotech sub-sector – a market flourishing with opportunity, innovation, and deep roots of medical possibilities. Fueled by an increasing volume of supportive research, cannabis-based biotech companies are addressing large markets of unmet medical need while rising to meet global demand of epic proportion. Included among several companies in the cannabis-biotech sub-sector is Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (LXRP Profile), a…

Continue Reading

WednesdayJul 26, 2017 9:00 am

Investment Options in the Multi-Billion Dollar Medical Marijuana Industry

CBDWire Editorial Coverage: Mounting research from around the world suggests marijuana’s potential to treat multiple medical conditions ranging from chronic pain to cancer, epilepsy, HIV/AIDS, anxiety and more.  Predicted to reach $55.8 billion by 2025(1), the global medical marijuana industry presents to investors a wide array of investment opportunities, driven by increasing demand for therapeutic applications of the drug. In turn, funds raised through the public market give marijuana companies the chance to raise capital to build stronger portfolios, increase their market reach and revenue, and offer cannabis-based alternatives to traditional medicine. Companies such as ChineseInvestors.com, Inc. (CIIX) (Profile: CIIX),…

Continue Reading

TuesdayJul 25, 2017 9:00 am

Potential Blockbuster Treatment for Alzheimer’s Disease Stands Out Among Medical Cannabis Companies

CBDWire Editorial Coverage: Changes in public opinion regarding cannabis have greatly fueled the fire blazing under the red-hot state-legalized marijuana market. A recent Gallup poll shows that 60 percent of Americans now support the legalization of marijuana1, while another report shows that marijuana sales jumped an incredible 30 percent in North America in 2016 to reach $6.7 billion2. While many investors are looking to find profitable plays in this burgeoning market, continuing federal restrictions make medical marijuana one of the safest investment routes. Standout companies that present prime opportunities in this space include India Globalization Capital, Inc. (NYSE MKT: IGC)…

Continue Reading

MondayJul 24, 2017 12:06 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Aims at Future of Cannabinoid Compound Treatment

Specializing in novel cannabinoid drug therapies, InMed Pharmaceuticals is well-poised for cannabinoid research and development of new treatments Glaucoma and skin disease pharmaceuticals now in development have an estimated $7.6 billion potential market InMed Pharmaceutical’s chief medical officer helped $3 billion GW Pharmaceuticals develop one of the first cannabis-based drugs With its proprietary bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is well-positioned to target the future of cannabinoid pharmaceutical compounds. InMed is a pre-clinical stage biopharmaceutical company specializing in the development of novel therapies through research and development of the…

Continue Reading

ThursdayJul 20, 2017 9:00 am

5 Standout Legal Cannabis Companies Worthy of Consideration

CBDWire Editorial Coverage: The legal marijuana market continues to gain momentum, driven by increasing public acceptance and an increasing number of investors looking for viable opportunities on a crowded playing field. According to a recent Gallup poll1, 60 percent of Americans now support the legalization of marijuana. As the playing field continues to grow in diversification and size, some of the most recognizable and frequently seen names are ChineseInvestors.com, Inc. (CIIX) (CIIX Profile), Terra Tech Corp. (TRTC), Medical Marijuana, Inc. (MJNA), Marijuana Company of America, Inc. (MCOA) and CV Sciences, Inc. (CVSI). The market presence of ChineseInvestors.com, Inc. (CIIX) is…

Continue Reading

WednesdayJul 19, 2017 9:25 am

ChineseInvestors.com (CIIX) Eyes Expansion in CBD Markets throughout North America

Sees opportunities in the fast-growing international medical marijuana market Plans store opening in San Gabriel, California, with online hemp-based product store already in Shanghai, China, targeting the global Chinese-speaking community Consilium Global Research projects that company revenues will reach $14.8 million by FY2020 ChineseInvestors.com, Inc. (OTCQB: CIIX) is employing a strategy of selling cannabidiol (CBD) in North America. It plans for a brick-and-mortar store in San Gabriel, California, as well as recently incorporating CBD Biotechnology, Inc., in British Columbia, Canada. It also has an online CBD store with hemp-based products located in the free trade zone of Shanghai, China, designed…

Continue Reading

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000